Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2015 Dec;76(6):1101-12. doi: 10.1007/s00280-015-2903-8. Epub 2015 Nov 12.

Antimitotic drugs in the treatment of cancer.

Author information

1
Department of Physiology, University of Pretoria, Private Bag x 323, Arcadia, 0007, South Africa.
2
Department of Physiology, University of Pretoria, Private Bag x 323, Arcadia, 0007, South Africa. michelle.visagie@up.ac.za.

Abstract

Cancer is a complex disease since it is adaptive in such a way that it can promote proliferation and invasion by means of an overactive cell cycle and in turn cellular division which is targeted by antimitotic drugs that are highly validated chemotherapy agents. However, antimitotic drug cytotoxicity to non-tumorigenic cells and multiple cancer resistance developed in response to drugs such as taxanes and vinca alkaloids are obstacles faced in both the clinical and basic research field to date. In this review, the classes of antimitotic compounds, their mechanisms of action and cancer cell resistance to chemotherapy and other limitations of current antimitotic compounds are highlighted, as well as the potential of novel 17-β estradiol analogs as cancer treatment.

KEYWORDS:

2-Methoxyestradiol; Epothilones; Estrogens; Taxanes; Vinca alkaloids

PMID:
26563258
PMCID:
PMC4648954
DOI:
10.1007/s00280-015-2903-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center